Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors

INTRODUCTION. Immune checkpoint inhibitors (ICIs) have changed the oncologic landscape in the past few years. Alongside impressive antitumor responses, new novel immune‐related adverse events (irAEs) have emerged; pneumonitis is an irAE that can potentially be fatal and necessitates a proper managem...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Asher, Nethanel, Marom, Edith M., Ben‐Betzalel, Guy, Baruch, Erez Nissim, Steinberg‐Silman, Yael, Schachter, Jacob, Shapira‐Frommer, Ronnie, Markel, Gal
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Immuno‐Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516115/
https://ncbi.nlm.nih.gov/pubmed/30777894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0352
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars